Evidence map›Paper›PMID 36038164›Full record

ArticleBMJ open2022

Biologically effective doses of 60-70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial.

Yusheng Ye, Xiaofei Zhu, Xianzhi Zhao, Lingong Jiang, Yangsen Cao, Huojun Zhang

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04603586 (A Prospective Phase Ⅱ Clinical Study of Stereotactic Radiotherapy Combined With Chemotherapy With Different Biological Effective Doses), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04603586 nacompletednot on this map

A Prospective Phase Ⅱ Clinical Study of Stereotactic Radiotherapy Combined With Chemotherapy With Different Biological Effective Doses (<70gy vs. >70Gy) in Locally Advanced Pancreatic Cancer

TypeinterventionalSponsorChanghai HospitalRan2020 to 2025Enrolled119ConditionsTreatmentArmsSBRT, Chemotherapy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer.Clinical and experimental gastroenterology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yusheng Ye *Department of Radiation Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.ORCID 0000-0002-5627-1593
Xiaofei Zhu *Department of Radiation Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Xianzhi Zhao *Department of Radiation Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.ORCID 0000-0003-4096-3349
Lingong JiangDepartment of Radiation Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Yangsen CaoDepartment of Radiation Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Huojun ZhangDepartment of Radiation Oncology, Changhai Hospital, Naval Medical University, Shanghai, China chyyzhj@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere is a paucity of studies about whether dose escalation of stereotactic body radiation therapy (SBRT) prolongs survival compared with de-escalation for patients with locally advanced pancreatic cancer (LAPC). Therefore, the aim of the study is to compare the survival benefits of biologically effective dose (BED METHODS AND ANALYSIS: This study is a single-centre, phase II trial. Patients with LAPC are randomly allocated to receive SBRT with BED ETHICS AND DISSEMINATION: The trial protocol has been approved by the Ethics committee of Shanghai Changhai Hospital. The ethics number is CHEC2020-100. Study results will be disseminated through peer-reviewed journals and released in related medical conferences. TRIAL REGISTRATION NUMBERS: NCT04603586.

Indexed as

Neoplasms, Second PrimaryPancreatic NeoplasmsRadiosurgeryChinaClinical Trials, Phase II as TopicHumansRandomized Controlled Trials as Topicpancreatic diseaseradiation oncologytoxicity

Identifiers

PMID36038164
PMCPMC9438046

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.